Therapeutic Role of Ursolic Acid on Ameliorating Hepatic Steatosis and Improving Metabolic Disorders in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Rats

Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This stud...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 9; no. 1; p. e86724
Main Authors Li, Songtao, Meng, Fanyu, Liao, Xilu, Wang, Yemei, Sun, Zongxiang, Guo, Fuchuan, Li, Xiaoxia, Meng, Man, Li, Ying, Sun, Changhao
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 29.01.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model. Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress. These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD.
AbstractList Background Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model. Methodology/Principal Findings Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-[alpha] was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-[alpha] significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress. Conclusions/Significance These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-[alpha] involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model. Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress. These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD.
BackgroundNon-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model.Methodology/principal findingsObese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress.Conclusions/significanceThese results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model. Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-[alpha] was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-[alpha] significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress. These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-[alpha] involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model.BACKGROUNDNon-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model.Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress.METHODOLOGY/PRINCIPAL FINDINGSObese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress.These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD.CONCLUSIONS/SIGNIFICANCEThese results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD.
Background Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model. Methodology/Principal Findings Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress. Conclusions/Significance These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD.
Background Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model. Methodology/Principal Findings Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress. Conclusions/Significance These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD.
Audience Academic
Author Sun, Zongxiang
Meng, Fanyu
Guo, Fuchuan
Li, Ying
Li, Songtao
Sun, Changhao
Li, Xiaoxia
Meng, Man
Wang, Yemei
Liao, Xilu
AuthorAffiliation Department of Nutrition and Food Hygiene, Harbin Medical University, Harbin, Heilongjiang province, P. R. China
CIMA. University of Navarra, Spain
AuthorAffiliation_xml – name: Department of Nutrition and Food Hygiene, Harbin Medical University, Harbin, Heilongjiang province, P. R. China
– name: CIMA. University of Navarra, Spain
Author_xml – sequence: 1
  givenname: Songtao
  surname: Li
  fullname: Li, Songtao
– sequence: 2
  givenname: Fanyu
  surname: Meng
  fullname: Meng, Fanyu
– sequence: 3
  givenname: Xilu
  surname: Liao
  fullname: Liao, Xilu
– sequence: 4
  givenname: Yemei
  surname: Wang
  fullname: Wang, Yemei
– sequence: 5
  givenname: Zongxiang
  surname: Sun
  fullname: Sun, Zongxiang
– sequence: 6
  givenname: Fuchuan
  surname: Guo
  fullname: Guo, Fuchuan
– sequence: 7
  givenname: Xiaoxia
  surname: Li
  fullname: Li, Xiaoxia
– sequence: 8
  givenname: Man
  surname: Meng
  fullname: Meng, Man
– sequence: 9
  givenname: Ying
  surname: Li
  fullname: Li, Ying
– sequence: 10
  givenname: Changhao
  surname: Sun
  fullname: Sun, Changhao
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24489777$$D View this record in MEDLINE/PubMed
BookMark eNqNk9tu1DAQhiNURA_wBggsISG4yOI4iZNwgbQqlK5UqNQDt9bEmey68tqL7VT0fXhQnO0WdasKoVwkmfn-357RzH6yY6zBJHmZ0UmWV9mHKzs4A3qyiuEJpTWvWPEk2cuanKWc0Xzn3vdusu_9FaVlXnP-LNllRVE3VVXtJb8vFuhghUNQkpxZjcT25NJ5q-P_VKqOWEOmS9TKOgjKzMkxrmCEzwNCsF55AqYjs-XK2esx_w0DtGv5Z-Wt69B5ogw5VvNFegQhRjGkM9MNEjvy3Zp0qqVdrAUxHW7IibpGN4oRPJIzCP558rQH7fHF5n2QXB59uTg8Tk9Ov84Opyep5A0LaZtlfUMzyjmnbZtTVtVUYstZVpeYtSVHWpac8T7nPQJ2WcU62tAa2oq3ec_zg-T1re9KWy82DfYiKxpWFow1NBKzW6KzcCVWTi3B3QgLSqwD1s0FuNgdjUIyBgV0dVUiFlLSlqHksmyznJUS2j56fdqcNrRL7CSa4EBvmW5njFqIub0WeUM5Leto8G5j4OzPAX0QS-Ulag0G7bC-dxG7QIvx3m8eoI9Xt6HmEAtQprfxXDmaimlR1XVeFryM1OQRKj4dLpWM09irGN8SvN8SRCbgrzCHwXsxOz_7f_b0xzb79h67QNBhEQc3jrI1fht8db_Tf1t8twYR-HgLSGe9d9gLqQKMPrE0pUVGxbhzd00T486Jzc5FcfFAfOf_T9kfmewxZQ
CitedBy_id crossref_primary_10_1016_j_jff_2017_09_056
crossref_primary_10_1016_j_cbi_2017_03_013
crossref_primary_10_1021_acsomega_2c06252
crossref_primary_10_1016_j_apjtm_2016_05_015
crossref_primary_10_1155_2024_5744974
crossref_primary_10_1111_cas_13425
crossref_primary_10_1016_j_bbrc_2017_08_101
crossref_primary_10_3389_fphar_2022_969207
crossref_primary_10_1016_j_phymed_2016_08_003
crossref_primary_10_3389_fmicb_2023_1183598
crossref_primary_10_3390_nu10111719
crossref_primary_10_1016_j_jff_2020_103781
crossref_primary_10_3390_foods11040497
crossref_primary_10_3390_pharmaceutics13060908
crossref_primary_10_3390_foods13142226
crossref_primary_10_1016_j_biopha_2017_08_071
crossref_primary_10_1016_j_jff_2021_104355
crossref_primary_10_1155_2019_8512048
crossref_primary_10_3390_ani14172492
crossref_primary_10_1007_s00204_015_1580_z
crossref_primary_10_3390_molecules26237243
crossref_primary_10_3892_etm_2021_10901
crossref_primary_10_3390_antiox13070797
crossref_primary_10_47115_bsagriculture_1194784
crossref_primary_10_1016_j_jff_2015_05_029
crossref_primary_10_1007_s13238_016_0295_0
crossref_primary_10_1016_j_ejphar_2021_174056
crossref_primary_10_3390_molecules28155645
crossref_primary_10_52547_rap_11_30_11
crossref_primary_10_1002_mnfr_201400670
crossref_primary_10_1039_C5FO00083A
crossref_primary_10_3390_nano11092196
crossref_primary_10_1007_s10522_023_10024_3
crossref_primary_10_1016_j_ejphar_2014_07_032
crossref_primary_10_1016_j_taap_2017_10_013
crossref_primary_10_3390_antiox11102041
crossref_primary_10_3390_biom15010140
crossref_primary_10_1016_j_jff_2019_03_048
crossref_primary_10_1080_00498254_2016_1234087
crossref_primary_10_3390_ijms20194767
crossref_primary_10_1371_journal_pone_0110711
crossref_primary_10_3390_cancers15082378
crossref_primary_10_3390_foods14030459
crossref_primary_10_3390_biomedicines11102845
crossref_primary_10_1038_cddis_2015_196
crossref_primary_10_4103_ijpvm_ijpvm_317_21
crossref_primary_10_1017_S2040174420000124
crossref_primary_10_4196_kjpp_2018_22_3_235
crossref_primary_10_1016_j_phrs_2023_106925
crossref_primary_10_1097_MCO_0000000000000159
crossref_primary_10_1111_obr_12523
crossref_primary_10_1039_D1FO00924A
crossref_primary_10_3390_antiox12040882
crossref_primary_10_1007_s00044_022_02982_z
crossref_primary_10_1002_jcb_30496
crossref_primary_10_1016_j_tifs_2016_11_019
crossref_primary_10_3892_mmr_2016_5172
crossref_primary_10_3390_nu9030198
crossref_primary_10_1002_pros_24026
crossref_primary_10_1016_j_fbio_2019_100489
crossref_primary_10_1080_13880209_2016_1214742
crossref_primary_10_1039_D1FO00661D
crossref_primary_10_1016_j_fbio_2024_104460
crossref_primary_10_1186_s12906_018_2420_5
crossref_primary_10_2147_JIR_S354878
crossref_primary_10_1186_s12906_022_03794_9
crossref_primary_10_1039_D0SC02922J
crossref_primary_10_1080_21623945_2020_1814545
crossref_primary_10_2174_1386207326666230119101011
crossref_primary_10_23736_S1121_421X_20_02738_5
crossref_primary_10_1016_j_phymed_2018_09_011
crossref_primary_10_1002_biof_1319
crossref_primary_10_1517_14728222_2014_944898
crossref_primary_10_1016_j_fitote_2020_104735
crossref_primary_10_2174_0929867330666221209102650
crossref_primary_10_1016_j_jff_2019_103691
crossref_primary_10_1017_S0007114517000228
crossref_primary_10_1155_2020_8370698
crossref_primary_10_3389_fphar_2020_00601
crossref_primary_10_2174_1570163816666190802153319
crossref_primary_10_26599_FSHW_2024_9250079
crossref_primary_10_1016_j_jphs_2019_04_001
crossref_primary_10_3390_nu12010040
crossref_primary_10_1002_crat_201500034
crossref_primary_10_3390_antiox10081161
crossref_primary_10_1002_fsn3_3105
crossref_primary_10_3390_nu12010201
crossref_primary_10_3390_diseases6030080
crossref_primary_10_1016_j_biopha_2018_08_019
crossref_primary_10_1016_j_biopha_2017_11_032
crossref_primary_10_1155_2020_8812634
crossref_primary_10_2174_1871530322666220408123746
crossref_primary_10_1016_j_toxrep_2020_04_005
crossref_primary_10_1089_jmf_2019_0154
crossref_primary_10_1111_jphp_12778
crossref_primary_10_4274_meandros_galenos_2021_32932
crossref_primary_10_1016_j_fct_2020_111537
crossref_primary_10_3748_wjg_v29_i37_5339
crossref_primary_10_47572_muskutd_725703
crossref_primary_10_1097_MEG_0000000000002483
crossref_primary_10_2174_1573407219666221024142326
crossref_primary_10_3390_molecules201119721
crossref_primary_10_1021_acs_jafc_5b06021
crossref_primary_10_1155_2019_9714302
crossref_primary_10_1111_1750_3841_15475
crossref_primary_10_1016_j_phrs_2020_104681
crossref_primary_10_1055_a_2277_4805
crossref_primary_10_1007_s12011_014_0064_y
crossref_primary_10_3390_ijms222212162
crossref_primary_10_1007_s10787_022_01038_3
Cites_doi 10.1016/j.numecd.2008.12.015
10.1002/mnfr.200900564
10.1002/hep.20170
10.1046/j.1440-1746.17.s1.10.x
10.2353/ajpath.2006.050953
10.1021/jm900872z
10.3390/molecules14062016
10.1152/ajpgi.00521.2005
10.1016/j.plipres.2008.08.001
10.1371/journal.pone.0037841
10.1002/mnfr.201100392
10.1002/hep.20177
10.1124/jpet.105.085597
10.1021/jf0520342
10.1016/j.phymed.2009.10.021
10.1021/jf802607x
10.1002/hep.24001
10.1016/j.plefa.2003.11.001
10.1093/carcin/21.5.983
10.1089/jmf.2010.0267
10.1210/me.2002-0120
10.1002/mnfr.200700389
10.1002/hep.1840400405
10.1007/s10620-009-1081-0
10.1016/0378-8741(95)90032-2
10.1155/2011/853501
10.2174/156652409787847191
10.1016/j.jhep.2006.02.011
10.1007/s00436-010-1740-2
10.1172/JCI200422422
10.1016/j.ijcard.2013.03.057
10.1093/jn/135.10.2313
10.1055/s-0028-1091986
10.1172/JCI27989
10.1194/jlr.R800089-JLR200
10.1016/S0168-8278(98)80073-1
10.1016/S0016-5085(98)70599-2
10.1007/s11010-005-9053-y
10.1016/j.cld.2004.04.006
10.1002/hep.1840220616
10.4149/gpb_2012_037
10.1503/cmaj.045232
10.1016/j.bbalip.2011.10.016
10.1074/jbc.M112.446575
10.1073/pnas.94.6.2557
10.1002/hep.20783
10.1016/j.jhep.2006.03.005
10.1016/j.bmcl.2011.07.095
10.1371/journal.pone.0039664
10.1371/journal.pone.0039332
ContentType Journal Article
Copyright COPYRIGHT 2014 Public Library of Science
2014 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2014 Li et al 2014 Li et al
Copyright_xml – notice: COPYRIGHT 2014 Public Library of Science
– notice: 2014 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2014 Li et al 2014 Li et al
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
3V.
7QG
7QL
7QO
7RV
7SN
7SS
7T5
7TG
7TM
7U9
7X2
7X7
7XB
88E
8AO
8C1
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AEUYN
AFKRA
ARAPS
ATCPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB.
KB0
KL.
L6V
LK8
M0K
M0S
M1P
M7N
M7P
M7S
NAPCQ
P5Z
P62
P64
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PTHSS
PYCSY
RC3
7X8
5PM
DOA
DOI 10.1371/journal.pone.0086724
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale in Context: Opposing Viewpoints
Gale in Context: Science
ProQuest Central (Corporate)
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Nursing & Allied Health Database (ProQuest)
Ecology Abstracts
Entomology Abstracts (Full archive)
Immunology Abstracts
Meteorological & Geoastrophysical Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Agricultural Science Collection
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database (Proquest)
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
Agricultural & Environmental Science Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Materials Science Collection
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Materials Science Database
Nursing & Allied Health Database (Alumni Edition)
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest Engineering Collection
Biological Sciences
Agricultural Science Database
Health & Medical Collection (Alumni)
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
ProQuest Engineering Database
Nursing & Allied Health Premium
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
Environmental Science Database
Materials Science Collection
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering Collection
Environmental Science Collection
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Agricultural Science Database
Publicly Available Content Database
ProQuest Central Student
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Meteorological & Geoastrophysical Abstracts
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Engineering Collection
Advanced Technologies & Aerospace Collection
Engineering Database
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Agricultural Science Collection
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Science Collection
Entomology Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
ProQuest Engineering Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Agricultural & Environmental Science Collection
AIDS and Cancer Research Abstracts
Materials Science Database
ProQuest Materials Science Collection
ProQuest Public Health
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Animal Behavior Abstracts
Materials Science & Engineering Collection
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE


MEDLINE - Academic


Agricultural Science Database


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Medicine
Biology
DocumentTitleAlternate Ursolic Acid Ameliorates NAFLD
EISSN 1932-6203
ExternalDocumentID 1492542290
oai_doaj_org_article_c22a4ad875ee4cc0b2ec6c5b1325cabf
PMC3906058
3195060981
A478835465
24489777
10_1371_journal_pone_0086724
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: NIAAA NIH HHS
  grantid: R00 AA023002
– fundername: NIAAA NIH HHS
  grantid: K99 AA023002
GroupedDBID ---
123
29O
2WC
53G
5VS
7RV
7X2
7X7
7XC
88E
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
AAUCC
AAWOE
AAYXX
ABDBF
ABIVO
ABJCF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
APEBS
ARAPS
ATCPS
BAWUL
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
BWKFM
CCPQU
CITATION
CS3
D1I
D1J
D1K
DIK
DU5
E3Z
EAP
EAS
EBD
EMOBN
ESX
EX3
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
IEA
IGS
IHR
IHW
INH
INR
IOV
IPY
ISE
ISR
ITC
K6-
KB.
KQ8
L6V
LK5
LK8
M0K
M1P
M48
M7P
M7R
M7S
M~E
NAPCQ
O5R
O5S
OK1
OVT
P2P
P62
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PTHSS
PYCSY
RNS
RPM
SV3
TR2
UKHRP
WOQ
WOW
~02
~KM
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
PJZUB
PPXIY
PQGLB
PV9
RIG
RZL
BBORY
PMFND
3V.
7QG
7QL
7QO
7SN
7SS
7T5
7TG
7TM
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
KL.
M7N
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
7X8
5PM
PUEGO
-
02
AAPBV
ABPTK
ADACO
BBAFP
KM
ID FETCH-LOGICAL-c692t-b11f90106660bb302780ceb62185e1b56e055626f36feaed172d0908ab76b3f63
IEDL.DBID M48
ISSN 1932-6203
IngestDate Fri Nov 26 17:12:45 EST 2021
Wed Aug 27 00:41:55 EDT 2025
Thu Aug 21 18:31:41 EDT 2025
Fri Jul 11 05:13:09 EDT 2025
Fri Jul 25 10:21:41 EDT 2025
Tue Jun 17 21:20:49 EDT 2025
Tue Jun 10 20:42:12 EDT 2025
Fri Jun 27 04:18:27 EDT 2025
Fri Jun 27 04:10:29 EDT 2025
Thu May 22 21:16:32 EDT 2025
Mon Jul 21 05:45:31 EDT 2025
Tue Jul 01 02:58:52 EDT 2025
Thu Apr 24 22:59:48 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
Creative Commons Attribution License
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c692t-b11f90106660bb302780ceb62185e1b56e055626f36feaed172d0908ab76b3f63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
Conceived and designed the experiments: SL YL CS. Performed the experiments: X. Liao FM YW X. Li MM. Analyzed the data: SL X. Liao. Contributed reagents/materials/analysis tools: FM YW. Wrote the paper: SL YL CS. Supplementary experiments for revising the manuscript: ZS FG.
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0086724
PMID 24489777
PQID 1492542290
PQPubID 1436336
PageCount e86724
ParticipantIDs plos_journals_1492542290
doaj_primary_oai_doaj_org_article_c22a4ad875ee4cc0b2ec6c5b1325cabf
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3906058
proquest_miscellaneous_1494302040
proquest_journals_1492542290
gale_infotracmisc_A478835465
gale_infotracacademiconefile_A478835465
gale_incontextgauss_ISR_A478835465
gale_incontextgauss_IOV_A478835465
gale_healthsolutions_A478835465
pubmed_primary_24489777
crossref_citationtrail_10_1371_journal_pone_0086724
crossref_primary_10_1371_journal_pone_0086724
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-01-29
PublicationDateYYYYMMDD 2014-01-29
PublicationDate_xml – month: 01
  year: 2014
  text: 2014-01-29
  day: 29
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Francisco
– name: San Francisco, USA
PublicationTitle PloS one
PublicationTitleAlternate PLoS One
PublicationYear 2014
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References RA Srivastava (ref38) 2006; 285
S Ferreira Dda (ref29) 2010; 106
P Tessari (ref50) 2009; 19
Z Liu (ref21) 2012; 7
E Ip (ref47) 2004; 39
T Fukao (ref43) 2004; 70
MS Rao (ref5) 2004; 40
SQ Yang (ref8) 1997; 94
MR Teli (ref9) 1995; 22
SK Erickson (ref20) 2009; 50
J Liu (ref12) 1995; 49
H Tilg (ref46) 2010; 52
CP Day (ref4) 1998; 114
G Musso (ref27) 2009; 48
A Laurent (ref53) 2004; 39
G Svegliati-Baroni (ref28) 2006; 169
F Sun (ref39) 2010; 17
ref6
P Lefebvre (ref7) 2006; 116
C Le May (ref42) 2005; 135
VS Rao (ref15) 2011; 14
N Rafiq (ref10) 2008; 28
I Pineda Torra (ref32) 2003; 17
R Hu (ref22) 2012; 7
SA Polyzos (ref49) 2009; 9
Y Ikeda (ref13) 2008; 52
LA Adams (ref48) 2005; 172
JF Silverman (ref19) 1990; 85
JK Reddy (ref30) 2006; 290
C Genet (ref34) 2010; 53
G Musso (ref40) 2009; 48
ref2
N Lu (ref24) 2008; 56
Y Li (ref14) 2010; 54
RH McMahan (ref36) 2013; 288
F Guo (ref25) 2011; 55
S Jager (ref11) 2009; 14
A Lonardo (ref51) 2006; 44
JD Browning (ref41) 2004; 114
B Jayaprakasam (ref18) 2006; 54
P Angulo (ref1) 2002; 17
K Hensley (ref52) 2000; 21
X Chen (ref35) 2011; 2011
SD Kunkel (ref16) 2012; 7
S Fiorucci (ref33) 2005; 315
OF James (ref3) 1998; 29
Y Jia (ref31) 2011; 21
JK Reddy (ref26) 2006; 290
A Sundaresan (ref17) 2012; 31
S Li (ref23) 2013; 168
XX Yu (ref37) 2005; 42
JR Lewis (ref44) 2010; 55
JW Haukeland (ref45) 2006; 44
PLoS One. 2014;9(3):e92364
References_xml – volume: 19
  start-page: 291
  year: 2009
  ident: ref50
  article-title: Hepatic lipid metabolism and non-alcoholic fatty liver disease
  publication-title: Nutr Metab Cardiovasc Dis
  doi: 10.1016/j.numecd.2008.12.015
– volume: 54
  start-page: 1609
  year: 2010
  ident: ref14
  article-title: Ursolic acid stimulates lipolysis in primary-cultured rat adipocytes
  publication-title: Mol Nutr Food Res
  doi: 10.1002/mnfr.200900564
– volume: 39
  start-page: 1286
  year: 2004
  ident: ref47
  article-title: Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice
  publication-title: Hepatology
  doi: 10.1002/hep.20170
– volume: 17
  start-page: S186
  year: 2002
  ident: ref1
  article-title: Non-alcoholic fatty liver disease
  publication-title: J Gastroenterol Hepatol
  doi: 10.1046/j.1440-1746.17.s1.10.x
– volume: 169
  start-page: 846
  year: 2006
  ident: ref28
  article-title: A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury
  publication-title: Am J Pathol
  doi: 10.2353/ajpath.2006.050953
– volume: 53
  start-page: 178
  year: 2010
  ident: ref34
  article-title: Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes
  publication-title: J Med Chem
  doi: 10.1021/jm900872z
– volume: 14
  start-page: 2016
  year: 2009
  ident: ref11
  article-title: Pentacyclic triterpene distribution in various plants - rich sources for a new group of multi-potent plant extracts
  publication-title: Molecules
  doi: 10.3390/molecules14062016
– volume: 290
  start-page: G852
  year: 2006
  ident: ref30
  article-title: Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation
  publication-title: Am J Physiol Gastrointest Liver Physiol
  doi: 10.1152/ajpgi.00521.2005
– volume: 48
  start-page: 1
  year: 2009
  ident: ref40
  article-title: Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
  publication-title: Prog Lipid Res
  doi: 10.1016/j.plipres.2008.08.001
– volume: 7
  start-page: e37841
  year: 2012
  ident: ref21
  article-title: A potent lead induces apoptosis in pancreatic cancer cells
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0037841
– volume: 55
  start-page: 1809
  year: 2011
  ident: ref25
  article-title: Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters
  publication-title: Mol Nutr Food Res
  doi: 10.1002/mnfr.201100392
– volume: 39
  start-page: 1277
  year: 2004
  ident: ref53
  article-title: Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis
  publication-title: Hepatology
  doi: 10.1002/hep.20177
– volume: 315
  start-page: 58
  year: 2005
  ident: ref33
  article-title: Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.105.085597
– volume: 54
  start-page: 243
  year: 2006
  ident: ref18
  article-title: Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas)
  publication-title: J Agric Food Chem
  doi: 10.1021/jf0520342
– volume: 17
  start-page: 669
  year: 2010
  ident: ref39
  article-title: Osthol regulates hepatic PPAR alpha-mediated lipogenic gene expression in alcoholic fatty liver murine
  publication-title: Phytomedicine
  doi: 10.1016/j.phymed.2009.10.021
– volume: 56
  start-page: 11526
  year: 2008
  ident: ref24
  article-title: Gossypin up-regulates LDL receptor through activation of ERK pathway: a signaling mechanism for the hypocholesterolemic effect
  publication-title: J Agric Food Chem
  doi: 10.1021/jf802607x
– volume: 52
  start-page: 1836
  year: 2010
  ident: ref46
  article-title: Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis
  publication-title: Hepatology
  doi: 10.1002/hep.24001
– volume: 290
  start-page: G852
  year: 2006
  ident: ref26
  article-title: Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation
  publication-title: American journal of physiology Gastrointestinal and liver physiology
  doi: 10.1152/ajpgi.00521.2005
– volume: 70
  start-page: 243
  year: 2004
  ident: ref43
  article-title: Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry
  publication-title: Prostaglandins Leukot Essent Fatty Acids
  doi: 10.1016/j.plefa.2003.11.001
– volume: 21
  start-page: 983
  year: 2000
  ident: ref52
  article-title: Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/21.5.983
– volume: 14
  start-page: 1375
  year: 2011
  ident: ref15
  article-title: Ursolic acid, a pentacyclic triterpene from Sambucus australis, prevents abdominal adiposity in mice fed a high-fat diet
  publication-title: J Med Food
  doi: 10.1089/jmf.2010.0267
– volume: 17
  start-page: 259
  year: 2003
  ident: ref32
  article-title: Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor
  publication-title: Mol Endocrinol
  doi: 10.1210/me.2002-0120
– volume: 52
  start-page: 26
  year: 2008
  ident: ref13
  article-title: Ursolic acid: an anti- and pro-inflammatory triterpenoid
  publication-title: Mol Nutr Food Res
  doi: 10.1002/mnfr.200700389
– volume: 85
  start-page: 1349
  year: 1990
  ident: ref19
  article-title: Liver pathology in morbidly obese patients with and without diabetes
  publication-title: Am J Gastroenterol
– volume: 40
  start-page: 783
  year: 2004
  ident: ref5
  article-title: PPARalpha in the pathogenesis of fatty liver disease
  publication-title: Hepatology
  doi: 10.1002/hep.1840400405
– volume: 55
  start-page: 560
  year: 2010
  ident: ref44
  article-title: Nonalcoholic fatty liver disease: a review and update
  publication-title: Dig Dis Sci
  doi: 10.1007/s10620-009-1081-0
– volume: 49
  start-page: 57
  year: 1995
  ident: ref12
  article-title: Pharmacology of oleanolic acid and ursolic acid
  publication-title: J Ethnopharmacol
  doi: 10.1016/0378-8741(95)90032-2
– volume: 2011
  start-page: 853501
  year: 2011
  ident: ref35
  article-title: TGR5: a novel target for weight maintenance and glucose metabolism
  publication-title: Exp Diabetes Res
  doi: 10.1155/2011/853501
– volume: 9
  start-page: 299
  year: 2009
  ident: ref49
  article-title: Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines
  publication-title: Curr Mol Med
  doi: 10.2174/156652409787847191
– volume: 44
  start-page: 1167
  year: 2006
  ident: ref45
  article-title: Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2006.02.011
– volume: 106
  start-page: 985
  year: 2010
  ident: ref29
  article-title: Trypanocidal activity and acute toxicity assessment of triterpene acids
  publication-title: Parasitol Res
  doi: 10.1007/s00436-010-1740-2
– volume: 114
  start-page: 147
  year: 2004
  ident: ref41
  article-title: Molecular mediators of hepatic steatosis and liver injury
  publication-title: J Clin Invest
  doi: 10.1172/JCI200422422
– volume: 168
  start-page: 2548
  year: 2013
  ident: ref23
  article-title: Calcium supplementation increases circulating cholesterol by reducing its catabolism via GPER and TRPC1-dependent pathway in estrogen deficient women
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2013.03.057
– volume: 135
  start-page: 2313
  year: 2005
  ident: ref42
  article-title: Fatty acids induce L-CPT I gene expression through a PPARalpha-independent mechanism in rat hepatoma cells
  publication-title: J Nutr
  doi: 10.1093/jn/135.10.2313
– volume: 28
  start-page: 427
  year: 2008
  ident: ref10
  article-title: Effects of weight loss on nonalcoholic fatty liver disease
  publication-title: Semin Liver Dis
  doi: 10.1055/s-0028-1091986
– volume: 48
  start-page: 1
  year: 2009
  ident: ref27
  article-title: Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
  publication-title: Progress in lipid research
  doi: 10.1016/j.plipres.2008.08.001
– volume: 116
  start-page: 571
  year: 2006
  ident: ref7
  article-title: Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis
  publication-title: J Clin Invest
  doi: 10.1172/JCI27989
– volume: 50
  year: 2009
  ident: ref20
  article-title: Nonalcoholic fatty liver disease
  publication-title: J Lipid Res
  doi: 10.1194/jlr.R800089-JLR200
– volume: 29
  start-page: 495
  year: 1998
  ident: ref3
  article-title: Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance
  publication-title: J Hepatol
  doi: 10.1016/S0168-8278(98)80073-1
– volume: 114
  start-page: 842
  year: 1998
  ident: ref4
  article-title: Steatohepatitis: a tale of two “hits”?
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(98)70599-2
– volume: 285
  start-page: 35
  year: 2006
  ident: ref38
  article-title: Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-005-9053-y
– ident: ref2
  doi: 10.1016/j.cld.2004.04.006
– volume: 22
  start-page: 1714
  year: 1995
  ident: ref9
  article-title: The natural history of nonalcoholic fatty liver: a follow-up study
  publication-title: Hepatology
  doi: 10.1002/hep.1840220616
– volume: 31
  start-page: 323
  year: 2012
  ident: ref17
  article-title: Ursolic acid and rosiglitazone combination alleviates metabolic syndrome in high fat diet fed C57BL/6J mice
  publication-title: General physiology and biophysics
  doi: 10.4149/gpb_2012_037
– volume: 172
  start-page: 899
  year: 2005
  ident: ref48
  article-title: Nonalcoholic fatty liver disease
  publication-title: CMAJ
  doi: 10.1503/cmaj.045232
– ident: ref6
  doi: 10.1016/j.bbalip.2011.10.016
– volume: 288
  start-page: 11761
  year: 2013
  ident: ref36
  article-title: Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M112.446575
– volume: 94
  start-page: 2557
  year: 1997
  ident: ref8
  article-title: Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.94.6.2557
– volume: 42
  start-page: 362
  year: 2005
  ident: ref37
  article-title: Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice
  publication-title: Hepatology
  doi: 10.1002/hep.20783
– volume: 44
  start-page: 1196
  year: 2006
  ident: ref51
  article-title: ‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2006.03.005
– volume: 21
  start-page: 5876
  year: 2011
  ident: ref31
  article-title: Ursolic acid is a PPAR-alpha agonist that regulates hepatic lipid metabolism
  publication-title: Bioorg Med Chem Lett
  doi: 10.1016/j.bmcl.2011.07.095
– volume: 7
  start-page: e39664
  year: 2012
  ident: ref22
  article-title: 6-Shogaol induces apoptosis in human hepatocellular carcinoma cells and exhibits anti-tumor activity in vivo through endoplasmic reticulum stress
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0039664
– volume: 7
  start-page: e39332
  year: 2012
  ident: ref16
  article-title: Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0039332
– reference: - PLoS One. 2014;9(3):e92364
SSID ssj0053866
Score 2.505381
Snippet Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and...
Background Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity,...
BackgroundNon-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity,...
Background Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity,...
SourceID plos
doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e86724
SubjectTerms Acid resistance
Acids
Animals
Biology
CD36 Antigens - genetics
CD36 Antigens - metabolism
Diabetes mellitus
Diacylglycerol O-Acyltransferase - genetics
Diacylglycerol O-Acyltransferase - metabolism
Diet
Diet, High-Fat
Dietary Fats - adverse effects
Disorders
Enzymes
Fatty liver
Fatty Liver - drug therapy
Fatty Liver - etiology
Fatty Liver - metabolism
Fatty Liver - pathology
Gene Expression
Health aspects
High fat diet
Insulin
Insulin Resistance
Laboratory animals
Lipase - genetics
Lipase - metabolism
Lipid metabolism
Lipid Metabolism - drug effects
Lipids
Liver
Liver - drug effects
Liver - metabolism
Liver - pathology
Liver diseases
Male
Medicine
Metabolic disorders
Metabolism
mRNA
Non-alcoholic Fatty Liver Disease
Obesity
Obesity - drug therapy
Obesity - etiology
Obesity - metabolism
Obesity - pathology
Oxidation resistance
Oxidative stress
Peroxisome proliferator-activated receptors
Plants (botany)
PPAR alpha - antagonists & inhibitors
PPAR alpha - genetics
PPAR alpha - metabolism
Rats
Rats, Sprague-Dawley
RNA
RNA, Messenger - genetics
RNA, Messenger - metabolism
RNA, Small Interfering - genetics
RNA, Small Interfering - metabolism
Rodents
Steatosis
Triterpenes - pharmacology
Ursolic Acid
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELbQnrggyl8DBQxCAg6mSZw48bEgqoIESNCi3iLbsdtIW2dFsgfehwdlJnFCgyqVA8eNx7vZmfF4xp75hpAXZWkTnRvJVJpKPLpRTGWFYFYWVkoHMbTBo4FPn8XRSfbxND-91OoLc8JGeOCRcfsmTVWmanCrrc2MiXVqjTC5higqN0o7tL6w503B1GiDYRULEQrleJHsB7m82bTeIqCpKNJssRENeP2zVV5t1m13lcv5d-bkpa3o8Da5FXxIejC--w65Yf0dshNWaUdfBSjp13fJr-M_5VUUEwlp6-gWW2TDZ2Wamraeqgu7bgZN8Gf03GKKtaEo_L7tmo4qX9NmOnqgF7YHtcHpdcDt7GjjKaIeM6d6eGp7BnE-aExNfeuZGnvwwgQY7n_SNSaC0HAvROFXu3vk5PD98bsjFvoyMCNk2jOdJA6zOiDyibXGi88yNlYL8BZylLywiNCTCseFs8rW4CPVsYxLpQuhuRP8PlnBC9hdQlUB4aEoZRnLMsscV9pwnSsOElcJ-EYR4ZOQKhNAy7F3xroabuIKCF5Gnlco2iqINiJsnrUZQTuuoX-L8p9pEXJ7eACKWAVFrK5TxIg8Re2pxvrV2XBUB9iggGPP-Yg8HygQdsNjXs-Z2nZd9eHL938g-vZ1QfQyELkW2GFUqKWA_4RwXgvKvQUlGA-zGN5FXZ-40kEkKNM8wyYAMHPS_6uHn83D-KWYq-dtux1oMo4110DzYFwuM2fBmSwh4igiUiwW0oL1yxHfnA-o51zGeIX_8H_I6hG5CY4vpl-xVO6RVf9jax-Dc9nrJ4Md-Q1mEn1k
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nj9MwELWgXLgglq8NLGAQEnAwm8SJk5xQQZSC2EUqW7S3yHacbqUSl0164P_wQ5lJnCxBK-DYeFwlHs94xn5-Q8izNDWBinXGZBhmuHUjmYwSwUyWmCwrIYfWuDVwdCzmy-jjaXzqNtxqB6vsfWLrqAurcY_8MEAWvQjZyV9vvzOsGoWnq66ExlVyLYCVBiFd6ex974nBloVw1-V4Ehw67bza2sogralIwmi0HLWs_YNvnmw3tr4s8PwTP_nbgjS7SW64SJJOO9XvkSumukX2nK3W9IUjlH55m_w8ubhkRRd2Y6gt6RILZcPvqV4X1FZ0-s1s1u18qFZ0bhBorSmifRtbr2sqq4IOGxD0yDQwebB7z95Z03VFETTCZrKBp6ZhWBVEm4Ie24pNu0q80AGamx_0E8JBsDOeDtGFbOo7ZDl7d_J2zlx1BqZFFjZMBUGJ2A7If3yl8Pgz9bVRAmKGGPUvDPL0hKLkojTSFBApFX7mp1IlQvFS8LtkUoEm9gmVCSSJIs1SP0ujqORSaa5iySNZyAAiJI_wXkm5dtTlWEFjk7fncQmkMN2Y56ja3KnWI2zote2oO_4h_wb1P8gi8Xb7wJ6vcmfHuQ5DCa8FWZ4xkda-Co0WOlaQ1MdaqtIjj3H25N0t1sF95FMsU8Cx8rxHnrYSSL5RIbpnJXd1nX_4_PU_hL4sRkLPnVBpYTi0dDcq4JuQ1GskeTCSBBeiR837ONf7UanzC2ODnv38v7z5ydCMf4qIvcrYXSsTcbx5DTL3OnMZRhZCyhTyjsQjyciQRkM_bqnWZy33Oc98PMi___fXekCuQ2CL8CoWZgdk0pzvzEMIHhv1qPUQvwCaLXCw
  priority: 102
  providerName: ProQuest
Title Therapeutic Role of Ursolic Acid on Ameliorating Hepatic Steatosis and Improving Metabolic Disorders in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Rats
URI https://www.ncbi.nlm.nih.gov/pubmed/24489777
https://www.proquest.com/docview/1492542290
https://www.proquest.com/docview/1494302040
https://pubmed.ncbi.nlm.nih.gov/PMC3906058
https://doaj.org/article/c22a4ad875ee4cc0b2ec6c5b1325cabf
http://dx.doi.org/10.1371/journal.pone.0086724
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELe27oUXxPhaxygGIQEPmfLpJA8IbVPLQNpAY0V9i2zH6SJ1TmlSib3w1_CHcpc4gaBO8BKp8TlJ78O-s8-_I-RlFClHBDK2uOvGuHTDLe6HzFJxqOI4gxha4tLA2Tk7nfofZ8Fsi7Q1Ww0Dy42hHdaTmq4Wh9-_3bwDg39bV20InbbT4bLQCuFKWej622QH5qYQaxqc-d2-Alg3Y-YA3W09ER4YYhbwi8LeXFVD-ncD92C5KMpNXunfyZV_zFaTe-SucTPpUaMXu2RL6ftk1xhySV8btOk3D8jPy98nsCjmGtIio2usog2_ucxTWmjKr9Uir5VFz-mVwixsSVE_qqLMS8p1SvN2dYJeqwo0C7unBtqzpLmmCIxsZbyCu6qycp2CUqVUF9riTZle6ADN1Q1dYK4INVtHFN5aPiTTyfjy5NQypRssyWK3soTjZJj4AcGRLQTujUa2VIKBQxGgcjCFID4uyzyWKa5SkFRqx3bERciElzHvERnAB6g9QnkI0mBRHNlx5PuZx4X0RMA9n6fcAfdpSLxWSIk0uOZYXmOR1Jt1IcQ3Dc8TlHJipDwkVtdr2eB6_IP-GOXf0SIqd32jWM0TY-SJdF0OnwUhoFK-lLZwlWQyEBDxB5KLbEieofYkzRHXbmxJjrCGgYdl6YfkRU2ByBwaU3_mfF2WyYdPX_-D6MtFj-iVIcoKYIfk5rgF_CdE_OpRHvQoYXyRveY91PWWKyUEi7Eb-FgnAHq2-r-5-XnXjA_FdD6tinVN43t4LBtoHjfm0nG2Nb4hCXuG1GN9v0XnVzUwuhfbuMu_f-szn5A74PBi2pXlxgdkUK3W6ik4lZUYke1wFsI1OnHwOnk_IjvH4_PPF6N6mWZUjyN4_TH-BbwDfzs
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELaWcoALYnltYWENAgEHs0mcOskBofIoLdsWaWlXewu245RKJSmbVGj_D2d-IzN5LUEr4LLHxuMo9YznYc98Q8hj3ze26umASccJ8OhGMul6gpnAM0EQQwyt8WhgMhXDufvhuHe8RX7WtTCYVlnrxEJRR6nGM_J9G1H0XEQnf7X-xrBrFN6u1i00SrE4MKffIWTLXo7eAn-fOM7g3ezNkFVdBZgWgZMzZdsx5iSA324phdd2vqWNEmDrevjdwiC-jCNiLmIjTQQWPrICy5fKE4rHgsN7L5HLLgdLjpXpg_e15gfdIURVnsc9e7-ShhfrNDEIoyo8x22Zv6JLQGMLOutVmp3n6P6Zr_mbARxcJ9cqz5X2S1HbJlsmuUG2K92Q0WcVgPXzm-TH7Kyoix6mK0PTmM6xMTf87utlRNOE9r-a1bKQv2RBhwYTuzXF7OI8zZYZlUlEmwMPOjE5CCtOr9FCM7pMKCapsIHM4anJGXYh0Sai0zRh_bLzL0yA4fyUjjH9BCfjbRQ9lHl2i8wvhG-3SScBTuwQKj0ISoUf-Fbgu27MpdJc9SR3ZSRt8Mi6hNdMCnUFlY4dO1Zhcf_nQchUrnmIrA0r1nYJa2atS6iQf9C_Rv43tAj0XTxITxZhpTdC7TgSPguiSmNcrS3lGC10T9nc6Wmp4i7ZQ-kJy6rZRl2FfWyLwLHTfZc8KigQ7CPBbKKF3GRZOPp49B9Enw5bRE8rojiF5dCyquCA_4QgYi3K3RYlqCzdGt5BWa9XJQvPNjfMrOX__OGHzTC-FDMEE5NuChqXY6U30Nwpt0uzsuDC-hDneF3itTZSa-nbI8nyS4G1zgMLEwfu_v2z9siV4WwyDsej6cE9chWcakztYk6wSzr5ycbcB8c1Vw8KbUHJ54tWT78A-XKsIA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGkRAviPFvhcEMAgEPoYmdOskDQmWjatlWUFmnvQXbcUqlkpQlFdr34VPw6bjLvxE0AS97bHyOGt_5fGf__DtCnvq-cVRfB5ZkLMCtG2lJ1xOWCTwTBDHk0Bq3Bg4nYjRz35_0TzbIz_ouDMIqa59YOOoo1bhH3nOQRc9FdvJeXMEiPu4N36y-WVhBCk9a63IapYnsm7PvkL5lr8d7oOtnjA3fHe2OrKrCgKVFwHJLOU6M-ASI4W2l8AjPt7VRAta9Pn6DMMg1w0TMRWykiWC1j-zA9qXyhOKx4PDeK-Sqxz0f55i_28BLwI8IUV3V457Tqyzj1SpNDFKqCo-5raWwqBjQrAud1TLNLgp6_8Ru_rYYDm-SG1UUSwel2W2SDZPcIpuVn8joi4rM-uVt8uPo_IIXnaZLQ9OYzrBIN_we6EVE04QOvprlorDFZE5HBkHemiLSOE-zRUZlEtFm84MemhwMF7vXzKEZXSQUASvWUObw1OQWViTRJqKTNLEGZRVg6ADN-Rk9QCgKdsaTKTqVeXaHzC5Fb3dJJwFNbBEqPUhQhR_4duC7bsyl0lz1JXdlJB2IzrqE10oKdUWbjtU7lmFxFuhB-lSOeYiqDSvVdonV9FqVtCH_kH-L-m9kkfS7eJCezsPKh4SaMQl_CzJMY1ytbcWMFrqvHM76Wqq4S3bQesLyBm3jusIBlkjgWPW-S54UEkj8keAUmst1loXjD8f_IfRp2hJ6XgnFKQyHltVtDvgmJBRrSW63JMF96VbzFtp6PSpZeD7RoWdt_xc3P26a8aWIFkxMui5kXI63vkHmXjldmpGFcNaHnMfrEq81kVpD325JFl8K3nUe2AgiuP_3v7VDroFjCg_Gk_0H5DrE14jysliwTTr56do8hBg2V48KZ0HJ58v2Tr8Ajh-wIQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+role+of+ursolic+acid+on+ameliorating+hepatic+steatosis+and+improving+metabolic+disorders+in+high-fat+diet-induced+non-alcoholic+fatty+liver+disease+rats&rft.jtitle=PloS+one&rft.au=Li%2C+Songtao&rft.au=Liao%2C+Xilu&rft.au=Meng%2C+Fanyu&rft.au=Wang%2C+Yemei&rft.date=2014-01-29&rft.eissn=1932-6203&rft.volume=9&rft.issue=1&rft.spage=e86724&rft_id=info:doi/10.1371%2Fjournal.pone.0086724&rft_id=info%3Apmid%2F24489777&rft.externalDocID=24489777
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon